A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression

Trial Profile

A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs ARX 788 (Primary)
  • Indications Breast cancer; Gastric cancer
  • Focus Adverse reactions; First in man
  • Sponsors Zhejiang Medicine
  • Most Recent Events

    • 26 Jun 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.
    • 26 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2018.
    • 17 Aug 2016 According to Ambrx media release, the US IND is active and will open US sites for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top